Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

• Váldodahkkit: Debbie Robbrecht (Dahkki), Jean‐Jacques Grob (Dahkki), Oliver Bechter (Dahkki), Matteo Simonelli (Dahkki), Bernard Doger (Dahkki), Ivan Borbath (Dahkki), Marcus O. Butler (Dahkki), Tina Cheng (Dahkki), Patricia Martin Romano (Dahkki), Elvire Pons‐Tostivint (Dahkki), Massimo Di Nicola (Dahkki), Giuseppe Curigliano (Dahkki), Min‐Hee Ryu (Dahkki), Alejo Rodriguez‐Vida (Dahkki), Dirk Schadendorf (Dahkki), Elena Garralda (Dahkki), Giovanni Abbadessa (Dahkki), Brigitte Demers (Dahkki), Amele Amrate (Dahkki), Hong Wang (Dahkki), Joon Sang Lee (Dahkki), Robert Pomponio (Dahkki), Rui Wang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract SAR439459, a 'second‐generation' human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This study reports the pharmacodynamics (PD) and biomarker r...